Clinical Trial

DESTINY-PANTUMOUR04

Study acronym: DP-04
Recruiting
View on ClinicalTrials.gov →
Summary
This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2025-08-13; most recent amendment 2026-07-21.
Status change: Not Yet Recruiting → Recruiting 2025-10-17
Trial Details
NCT Number NCT07124000
Lead Sponsor AstraZeneca
Conditions Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastrointestinal Stromal Tumour +19 more
Enrollment 100 participants
Start Date 2025-09-18
Primary Completion 2028-03-30 (estimated)
Study Completion 2028-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-22